PROCEDURAL STEPS TAKEN AFTER GRANTING THE MARKETING 
AUTHORISATION 
For procedures finalised after 01 October 2003, please refer to module 8B 
• 
• 
• 
• 
• 
• 
The MAH submitted to the EMEA on 12 July 1999 application for a Type I variation, a 
minor change of the manufacturing process of the active substance. Pursuant to Article 
4  of  Commission  Regulation  (EC)  No  542/95  of  10  March  1995,  as  amended.  The 
procedure  started  on  30  July  1999.  A  positive  opinion  was  adopted  by  the  CPMP  20 
October 1999. (EMEA/H/C/232/I/01)  
The  MAH  submitted  on  21  September  1999  a  notification  to  the  EMEA  in  order  to 
introduce  changes  to  the  Package  Leaflet  not  connected  to  the  Summary  of  Product 
Characteristics,  pursuant  Article  10(3)  of  Council  Directive  No.  92/27/EEC  of  31 
March 1992. The procedure started on 21 September 1999. The notification was signed 
by the Head of Human Medicines Evaluation Unit on 18 October 1999 and forwarded 
to  the  European  Commission  which  adopted  a  decision  on  31  January  2000. 
(EMEA/H/C/232/N/02) 
The  MAH  submitted  to  the  EMEA  on  30  September  1999  application  for  a  Type  I 
variation,  replacement  of  bovine-derived  excipient  with  a  comparable  vegetable-
derived excipient, pursuant to Article 4 of Commission Regulation (EC) No 542/95 of 
10 March 1995. The procedure started on 4 October 1999. A positive notification was 
signed  by  the  Head  of  Human  Unit  at  the  EMEA  on  18  October  1999.  and  the 
European  Commission  which  adopted  a  decision  on  21  October  1999. 
(EMEA/H/C/232/I/03) 
The  MAH  submitted  to  the  EMEA  on  11  January  2000  an  application  for  a  Type  I 
variation,  a  change  of  specification  of  active  substance,  pursuant  to  Article  4  of 
Commission  Regulation  (EC)  No  542/95  of  10  March  1995,  as  amended.  The 
procedure started on 18 January 2000. A positive notification was signed by the Head 
ofby  the  Head  of  the  Biologicals  and  Biotechnology  sector  in  the  Unit  for  the 
Evaluation  of  Medicines  for  Human  Use  at  the  EMEA  16  February  2000  and  the 
European  Commission  which 
a  decision  on  1  March  2000.  
(EMEA/H/C/232/I/04) 
adopted 
The  MAH  submitted  on  26  January  2000  a  notification  to  the  EMEA  in  order  to 
introduce  changes  to  the  Package  Leaflet  not  connected  to  the  Summary  of  Product 
Characteristics,  pursuant  Article  10(3)  of  Council  Directive  No.  92/27/EEC  of  31 
March 1992. The procedure started on 2 February 2000. The notification was signed by 
Head  of  the  Biologicals  and  Biotechnology  sector  in  the  Unit  for  the  Evaluation  of 
Medicines  for  Human  Use  at  the  EMEA  on  17  February  2000  and  forwarded  to  the 
European  Commission  which 
a  decision  on  6  April  2000. 
(EMEA/H/C/232/N/05) 
adopted 
The  MAH  submitted  to  the  EMEA  on  June  2000  application  for  a  Type  I  variation 
change  following  modifications  to  the  manufacturing  authorisation  in  order  to  apply 
Wyeth Laboratories, UK as the manufacturing responsible for the batch release and to 
replace  the  current  one,  pursuant  to  Article  4  of  Commission  Regulation  (EC)  No 
542/95  of  10  March  1995,  as  amended.  The  procedure  started  on  14  June  2000.  A 
positive  notification  was  signed  by  the  Head  of  Head  of  the  Biologicals  and 
Biotechnology sector in the Unit for the Evaluation of Medicines for Human Use at the 
EMEA on 27 June 2000 and forwarded to the European Commission which adopted a 
decision on 11 August 2000. (EMEA/H/C/232/I/06) 
1/2 
EMEA 2004 
 
 
 
Subsequent  post  Marketing  Authorisation  applications  agreed  upon  are  summarised  in  the 
table below: 
Scope 
Application 
number 
Type of 
modification1 
Notification/ 
Opinion 
issued on2 
Change in the name and/or address of the marketing authorisation 
holder 
Change in pack size for a medicinal product 
Update of or change(s) to the pharmaceutical documentation 
Quality changes 
Addition of a manufacturing facility and two fold scale-up of 
purification process 
Additional drug product facility 
Update of the SPC (point 4.8) 
Compliance with Core SPC for human plasma 
Change in supplier of an intermediate compound used in 
manufacture of the active substance 
Change in the name of manufacturer 
New stopper for sodium chloride diluent 
Line Extension 
Scale-up of MAb sepharose chromatography resin coupling process 
Elimination of amino acid analysis testing on incoming KGSF 14 
media 
Minor change in labelling or package leaflet not connected with the 
SPC (Art. 61.3 Notification) 
Quality changes 
Change(s) to the test method(s) and/or specifications for the active 
substance 
Transfer of Marketing Authorisation Holder 
Change in or addition of manufacturing site(s) for part or all of the 
manufacturing process and Change in the name of a manufacturer of 
the active substance 
Minor change of manufacturing process of the active substance 
Extension of shelf-life or retest period of the active substance 
I/07 
I/08 
II/09 
II/010 
II/012 
II/013 
II/014 
II/015 
I/016 
I/020 
II/021 
X/022 
II/023 
II/024 
N/025 
II/026 
II/027 
T//028 
I/029 
I/030 
I/035 
I 
I 
II 
II 
II 
II 
II 
II 
I 
I 
II 
X 
II 
II 
N 
II 
II 
T 
I 
I 
I 
Commission 
Decision 
Issued/amen
ded on 
27.12.00 
03.09.01 
31.10.01 
23.01.02 
23.01.02 
25.06.02 
20.08.02 
31.10.01 
28.02.02 
29.04.02 
19.12.02 
10.12.02 
21.10.02 
06.10.00 
12.12.00 
23.08.01 
18.10.01 
17.01.02 
17.01.02 
21.02.02 
24.04.02 
29.10.01 
29.01.02 
24.04.02 
19.09.02 
21.11.02 
17.10.02 
23.08.02 
18.09.02 
20.02.03 
20.03.03 
31.03.03 
18.07.03 
08.05.03 
26.03.03 
15.05.03 
22.07.03 
25.09.03 
02.10.03 
22.09.03 
23.09.03 
1 In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: I refers 
to a minor variation (Type I variation); II refers to a major variation (Type II variation); I/II refers to a 
minor variation following the procedure set out in Article 6, 7 and 8 of the Regulation; X refers to an 
Annex II application. 
T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) 
No 2141/96 of 7 November 1996.  
N refers to a notification in accordance with Article 10(3) of Council Directive 92/27/EEC of 31 March 
1992. 
2 For Notifications and Type I variations, the date of entry into force of the change is the EMEA 
Notification date. The Commission Decision will be amended accordingly. 
2/2 
EMEA 2004 
 
 
 
 
 
 
 
 
 
 
 
 
                                                            
 
